VimRx Pharmaceuticals Inc. has shipped its VimRxyn hypericintreatment for AIDS to the National Institutes of Health forPhase I clinical trials. The trials will be conducted by theNational Institute of Allergy and Infectious Diseases.

Beginning of clinical trials was delayed when VimRx hadproblems preparing a formulation of VimRxyn and by NIH'sprocessing of the submission, according to corporatecontroller, Rob McKinney. VimRx (NASDAQ:VMRX) of Stamford,Conn., is developing therapeutics derived from naturalsubstances. Hypericin is a plant derivative of St. John's wort.

(c) 1997 American Health Consultants. All rights reserved.